Resona Asset Management Co. Ltd. Lowers Holdings in Intuitive Surgical, Inc. $ISRG

Resona Asset Management Co. Ltd. lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 212,119 shares of the medical equipment provider’s stock after selling 31,867 shares during the quarter. Intuitive Surgical accounts for about 0.6% of Resona Asset Management Co. Ltd.’s holdings, making the stock its 24th biggest position. Resona Asset Management Co. Ltd.’s holdings in Intuitive Surgical were worth $120,612,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Brighton Jones LLC lifted its holdings in Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after acquiring an additional 731 shares during the period. Sivia Capital Partners LLC lifted its holdings in Intuitive Surgical by 3.8% in the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares during the period. Schnieders Capital Management LLC. lifted its holdings in Intuitive Surgical by 38.0% in the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 268 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Intuitive Surgical in the second quarter valued at $200,000. Finally, Main Street Financial Solutions LLC lifted its holdings in Intuitive Surgical by 92.4% in the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after acquiring an additional 1,407 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $439.92 on Tuesday. Intuitive Surgical, Inc. has a 1 year low of $417.74 and a 1 year high of $603.88. The stock has a market capitalization of $155.80 billion, a P/E ratio of 53.32, a PEG ratio of 3.36 and a beta of 1.51. The stock has a 50-day simple moving average of $462.50 and a 200-day simple moving average of $513.03.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. Analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amy L. Ladd sold 119 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total transaction of $55,156.50. Following the completion of the sale, the director owned 120 shares in the company, valued at approximately $55,620. The trade was a 49.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia L. Wadors sold 220 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $499.71, for a total value of $109,936.20. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 5,647 shares of company stock worth $2,760,359. Company insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

ISRG has been the subject of several research reports. Barclays set a $651.00 price target on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. BTIG Research reaffirmed a “buy” rating and set a $574.00 price target on shares of Intuitive Surgical in a research note on Wednesday, April 22nd. Robert W. Baird lifted their price target on Intuitive Surgical from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Raymond James Financial dropped their price objective on Intuitive Surgical from $615.00 to $577.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Finally, Argus dropped their price objective on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Nineteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $579.33.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.